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Xmanagement algorithm is designed to recognize that the ex-
tracorporeal technology that will effectively bridge a patient
with cystic fibrosis with hypercapnic respiratory failure is
markedly different than the device technology required to
support a patient with idiopathic pulmonary fibrosis with
cor pulmonale and PEA arrest. The clinical goal is an am-
bulatory patient without respiratory failure and a risk profile
for transplantation significantly less than that at the initia-
tion of initial ECMO support. This clinical thought process
mirrors that of current ventricular assist device management
paradigms in cardiac transplantation.
The broad application of artificial lung technologies to
support patients with advanced lung disease has significant
public health and policy implications. Most UNOS wai-
tlisted patients described in the present report underwent
emergent cannulation in the context of progressive disease
(eg, accelerated decompensation phase of pulmonary fibro-
sis with secondary pulmonary hypertension and cardiopul-
monary collapse). An additional group of patients had
parenchymal disease not amenable to traditional support
with mechanical ventilation (eg, uncontrolled bronchopleu-
ral fistula in cystic fibrosis). Transplantation before decom-
pensation would have precluded the need for mechanical
support. As noted in the outcomes analysis, our institutional
UNOS waitlisted patients with LAS scores greater than 50
who avoided ECMO support had a significant survival ad-
vantage. An analysis of lung transplants performed from
May 2006 to December 2006within UNOS region 5 demon-
strated that only 4% of transplanted patients had LAS scores
greater than 70 (unpublished data). LAS scoreswithin the lo-
cal donor-specific area were predictive, with the waiting
time reduced by one half for every 5 points greater than an
LAS score of 30. The estimated wait time for a patient
with an LAS score greater than 50 was less than 14 days.
Had organ allocation been regionalized rather than local, it
is possible that several patients ‘‘rescued’’ with an ECMO
bridge might have undergone transplantation before clinical
decompensation. A discussion of more ‘‘regionalized’’
(nonlocal) allocation of pulmonary allografts—similar to
that currently in place for cardiac allografts—is warranted.
CONCLUSIONS
The use of extracorporeal technologies to salvage,
rehabilitate, and, subsequently, transplant patients with
nonrecoverable lung disease is technically doable and
logistically feasible. Progression of chronic disease with
unpredictable and fulminant decompensation (pulmonary
fibrosis and pulmonary hypertension), mechanical compli-
cations of an established lung disease (bronchopleural fis-
tula in cystic fibrosis), and respiratory failure syndromes
without efficacious medical therapy (pulmonary veno-
occlusive disease) are the diagnostic categories most likely
to demonstrate a survival benefit from the application
of extracorporeal mechanical support. Algorithm-directedThe Journal of Thoracic and Camanagement of ECMO deployment can improve survival.
An informed registry of the relevant parameters predicting
successful usage of current technologies is necessary and
discussion of an appropriately constructed clinical trial is
warranted.
Some of the data used in the present report were from the UNOS
database and the participating centers. UNOS did not review the
analysis and is not responsible for our conclusions.
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Dr Michael S. Mulligan (Seattle, Wash). Thanks, Chuck. That
represents a lot of work. Very nice paper, and certainly you have
done a lot to push the envelope and advance the field. I have
a few questions for you.
The first is that I notice there were 5 nonretransplant patients
with cystic fibrosis (CF). When they present hypoxic and in hyper-
carbic failure, they are intubated and then begin to retain infected
secretions. Their time on the ventilator is very poorly tolerated and
often quickly progress to sepsis. Conversely, the ‘‘crashing idio-
pathic pulmonary fibrosis (IPF)’’ patient historically does poorly
in long-term outcomes. I was wondering how the patients withrdiovascular Surgery c Volume 145, Number 3 867
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XCF fared and is this something we can do to provide advantages for
them going forward?
Dr Hoopes. From our perspective, patients with CF are ideal
patients because they are less unstable hemodynamically when
they present. For patients with CF, we have deployed ECMO in
response to mechanical complications of the disease, primarily
complications of uncontrolled bronchopleural fistula when
patients could not be adequately ventilated. We have very few
absolute exclusions to transplant, but we will not transplant
someone who is not ambulatory. In the past 4 years, CF patients
with profound hypoxia or hypercarbia secondary to disease
burden who have required mechanical ventilation have under-
gone tracheostomy and transition to venovenous ECMO with
the expectation that they all become ambulatory prior to
transplantation.
Dr Mulligan. So perhaps you are intervening a bit earlier than
some of the other centers. Intervening later seems to be associated
with survival outcomes that are not quite as good.
The second question I have for you relates to the LAS scoring.
Currently, if you consider all theUNOSdata, the use ofpretransplant
ECMO carries a post-transplant odds ratio for mortality of 7. Your
own institutional data showed a negative effect on outcomes, and,
currently in theUNOSbylaws, noLAS adjustment ismade for being
on ECMO. Given that so many of your patients were listed patients,
how did you adjust the LAS score when they went on ECMO?
Dr Hoopes. LAS scores reflect the amount of oxygen and the
need for mechanical ventilation as the vast majority of patients
were intubated and transitioned from mechanical ventilation to
ECMO support. From a philosophical standpoint, I would argue
that we are going to ultimately end up the same place we are
when we consider our cardiac patients with ventricular assist868 The Journal of Thoracic and Cardiovascular Surgdevices. We will actually start lowering the scores of patients on
ECMO and deprioritizing them, not increasing their priority score
because they would be more stable and actually reperesent a lower
risk profile recipient. As you note, currently ECMO cannot be
effectively integrated into the LAS system. Nonetheless, in the
majority of patients, life-sustaining extracorporeal life support is
inherently unstable and we have listed them as though they were
receiving mechanical ventilation.
Dr Mulligan. The last question relates to your call for regional
sharing. The benefits to critically ill recipients have been outlined;
however, significant issues exist with implementing such strate-
gies. Specifically, one would have to very carefully standardize
the listing behavior and practices to avoid ‘‘gaming’’ of the sys-
tem. One would also have to try to make organ acceptance behav-
iors fairly uniform. Can you speak to some of these barriers to
regional sharing?
Thank you very much. Excellent paper.
Dr Hoopes. We are in total agreement. My frustration with
transplantation is that it is not currently studied as a public health
issue. It is currently viewed as ‘‘my list versus your list,’’ and I do
not think, under the current system, it would be possible to actually
make an LAS system that takes into account regionalization versus
local program interests. What I would advocate for in the long run
is regionalization of transplantation as a public health resource.
Perhaps not all transplant centers need to provide artificial lung
technologies. How national health care policy would establish re-
gional referral centers, what such centers would actually do, and
how they would be structured and reimbursed would obviously
be contentious. As you know, regionalization has been discussed
in the past and the political wherewithal to truly study the issue
has been missing.ery c March 2013
